DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Rilutek (Riluzole) - Summary



RILUTEKĀ® (riluzole) is a member of the benzothiazole class.

RILUTEK is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS). Riluzole extends survival and/or time to tracheostomy.

See all Rilutek indications & dosage >>


Media Articles Related to Rilutek (Riluzole)

Virginia Tech Carilion Research Institute scientists unexpectedly find ALS affects sensory neurons involved in movement
Source: Muscular Dystrophy / ALS News From Medical News Today [2015.11.24]
The same nerves that keep a person from crushing a flower or dropping a water glass are teaching scientists something new about amyotrophic lateral sclerosis.

Good neighbours turn bad: Helper cells in the brain could hold the clue to Motor Neuron Disease
Source: Muscular Dystrophy / ALS News From Medical News Today [2015.10.19]
A new study on amyotrophic lateral sclerosis (ALS) puts star-shaped helper cells in the brain, called astrocytes, in the spotlight.

Mixed up cell transportation key piece of ALS and dementia puzzle
Source: Muscular Dystrophy / ALS News From Medical News Today [2015.10.06]
It's the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), but until now scientists weren't sure how a specific gene caused these devastating diseases.

more news >>

Published Studies Related to Rilutek (Riluzole)

12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder. [2014]
Many children with childhood-onset obsessive-compulsive disorder (OCD) fail to respond adequately to standard therapies... However, future studies may show benefits for less treatment-refractory children with fewer concomitant medications.

Riluzole decreases flexion withdrawal reflex but not voluntary ankle torque in human chronic spinal cord injury. [2011.06]
The objectives of this study were to probe the contribution of spinal neuron persistent sodium conductances to reflex hyperexcitability in human chronic spinal cord injury... These results suggest that intrinsic spinal cellular excitability could be a target for managing chronic spinal cord injury hyperreflexia impairments without causing a significant loss in volitional strength.

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. [2010.05]
BACKGROUND: In a pilot study, lithium treatment slowed progression of amyotrophic lateral sclerosis (ALS). We aimed to confirm or disprove these findings by assessing the safety and efficacy of lithium in combination with riluzole in patients with ALS... INTERPRETATION: We found no evidence that lithium in combination with riluzole slows progression of ALS more than riluzole alone. The time-to-event endpoint and use of prespecified interim analyses enabled a clear result to be obtained rapidly. This design should be considered for future trials testing the therapeutic efficacy of drugs that are easily accessible to people with ALS. FUNDING: National Institute of Neurological Disorders and Stroke, ALS Association, and ALS Society of Canada. Copyright 2010 Elsevier Ltd. All rights reserved.

Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. [2010.03.09]
BACKGROUND: The pleiotropic effects of riluzole may antagonize common mechanisms underlying chronic cerebellar ataxia, a debilitating and untreatable consequence of various diseases... CONCLUSIONS: These findings indicate the potential effectiveness of riluzole as symptomatic therapy in diverse forms of cerebellar ataxia. Classification of evidence: This study provides Class I evidence that riluzole reduces, by at least 5 points, the ICARS score in patients with a wide range of disorders that cause cerebellar ataxia (risk difference 63.2%, 95% CI 33.5%-79.9%).

Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. [2010.02]
The N-methyl-D-aspartate (NMDA) glutamate receptor antagonist ketamine may have rapid, albeit transient, antidepressant properties. This study in patients with treatment-resistant major depression (TRD) aimed to (1) replicate the acute efficacy of single-dose intravenous (i.v.) ketamine; (2) test the efficacy of the glutamate-modulating agent riluzole in preventing post-ketamine relapse; and (3) examine whether pretreatment with lamotrigine would attenuate ketamine's psychotomimetic effects and enhance its antidepressant activity.

more studies >>

Clinical Trials Related to Rilutek (Riluzole)

Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD) [Recruiting]
The purpose of this study is to determine whether Riluzole is effective in the augmentation treatment of post-traumatic stress disorder (PTSD) that is experienced by Active Duty military service members and Operation Enduring Freedom (OEF), Operation Iraqi Freedom (OIF), and Operation New Dawn (OND) veterans who have not had symptom reduction after one or more kinds of medications or therapies.

Efficacy and Tolerability of Riluzole in Treatment Resistant Depression [Active, not recruiting]

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma [Recruiting]
This phase I trial studies the side effects and best dose of sorafenib tosylate when given together with riluzole in treating patients with advanced solid tumors or melanoma. Riluzole may stop or slow the growth of tumor cells. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving riluzole together with sorafenib tosylate may kill more tumor cells.

Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders [Completed]
This study will examine the effectiveness of riluzole for treating Obsessive-Compulsive Disorder in Youth, Including those with Autism Spectrum Disorders.

Riluzole Augmentation Pilot in Depression (RAPID) Trial [Recruiting]
The investigators are doing a research study to find out if riluzole, when taken along with a standard antidepressant (sertraline) can help people with major depression. This research study will compare riluzole + sertraline to placebo + sertraline. The investigators hypothesize that adding riluzole will lead to a better antidepressant response, in less time, then sertraline alone.

more trials >>

Reports of Suspected Rilutek (Riluzole) Side Effects

Death (4)Pyrexia (3)Agranulocytosis (3)Respiratory Failure (3)Confusional State (2)Pulse Abnormal (2)Pallor (2)Hypokalaemia (2)OFF Label USE (2)Weight Increased (2)more >>

Page last updated: 2015-11-24

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015